{"id":"W2164035913","doi":"10.1200/jco.2012.46.0543","title":"Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type <i>K-RAS</i> Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hotel Dieu Hospital","funders":"National Health and Medical Research Council; Bristol-Myers Squibb; Centre Hospitalier Universitaire de Québec; National Cancer Institute; University of Toronto; Flinders University; Monash University; Peter MacCallum Cancer Centre; University of New South Wales; Medical Research Council; University of Ottawa; Queen's University; Amgen","keywords":"Medicine; Cetuximab; Internal medicine; Clinical endpoint; Placebo; Hazard ratio; Colorectal cancer; Oncology; Population; Phases of clinical research; Chemotherapy; Gastroenterology; Urology; Surgery; Cancer; Clinical trial; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002066339,0.002680733,0.004627447,0.0005869911,0.0005952238,0.001584705,0.001488741,0.002822338,0.008529406],"category_scores_gemma":[0.002288194,0.0009566005,0.001871655,0.0006111891,0.001772155,0.001405594,0.0005016503,0.004354447,0.00188396],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001382695,"about_ca_system_score_gemma":0.001867686,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001603662,"about_ca_topic_score_gemma":0.003416576,"domain_scores_codex":[0.9992732,0.0003639668,0.00003801953,0.0001432286,0.00005733408,0.0001242291],"domain_scores_gemma":[0.9988804,0.0002385625,0.0003148073,0.0000812217,0.00007981368,0.0004051515],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9881178,0.004627358,0.0001580101,0.0003113589,0.0004202524,0.00001799211,0.00002112701,0.0001816137,0.0009930702,0.00006833311,0.000681519,0.004401474],"study_design_scores_gemma":[0.9687402,0.02985928,0.0004301349,0.0000171574,0.0001614106,0.00001292489,0.000009575428,0.0002236414,0.000139606,0.00008459781,0.000313814,0.000007656522],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9683028,0.008271222,0.001239917,0.001502528,0.001968474,0.01107666,0.002171373,0.0003620507,0.005104879],"genre_scores_gemma":[0.969865,0.00414364,0.001858307,0.002523275,0.0009441099,0.01280432,0.002086226,0.00005753689,0.005717654],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008529406,"threshold_uncertainty_score":0.0285337,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1050762737576454,"score_gpt":0.4537744715422363,"score_spread":0.3486981977845909,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}